HCM vs. UTHR, VTRS, RDY, SRPT, CTLT, ELAN, ROIV, INSM, LEGN, and ASND
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include United Therapeutics (UTHR), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
HUTCHMED (NASDAQ:HCM) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
United Therapeutics received 259 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.60% of users gave HUTCHMED an outperform vote while only 61.84% of users gave United Therapeutics an outperform vote.
United Therapeutics has a net margin of 42.05% compared to HUTCHMED's net margin of 0.00%. United Therapeutics' return on equity of 18.72% beat HUTCHMED's return on equity.
United Therapeutics has higher revenue and earnings than HUTCHMED.
8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 12.5% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, United Therapeutics had 12 more articles in the media than HUTCHMED. MarketBeat recorded 17 mentions for United Therapeutics and 5 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.01 beat United Therapeutics' score of 0.76 indicating that HUTCHMED is being referred to more favorably in the media.
HUTCHMED currently has a consensus target price of $29.70, indicating a potential upside of 67.23%. United Therapeutics has a consensus target price of $309.44, indicating a potential upside of 12.53%. Given HUTCHMED's higher possible upside, research analysts clearly believe HUTCHMED is more favorable than United Therapeutics.
HUTCHMED has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
Summary
United Therapeutics beats HUTCHMED on 12 of the 16 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
